A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus

Gerlinde R. Van de Walle; Maeva A. May; Sarah T. Peters; Stephan M. Metzger; Cristina T. Rosas; Nikolaus Osterrieder

doi:10.1016/j.vaccine.2009.10.123

A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus

Gerlinde R. Van de Walle, Maeva A. May, Sarah T. Peters, Stephan M. Metzger, Cristina T. Rosas, Nikolaus Osterrieder^*

^*Corresponding author for this work

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

26 Citations (Scopus)

Abstract

Vaccination is commonly used to control equine respiratory pathogens such as equine herpesvirus type 1 (EHV-1) and equine influenza virus (EIV). Here, we describe the generation and characterization of a recombinant EHV-1 modified live virus vaccine (MLV) based on a recent abortogenic EHV-1 strain, NY03. The immunogenicity and efficacy of the MLV was tested in horses in an EHV-1 vaccination/challenge experiment using the highly virulent neurovirulent EHV-1 strain OH03. Induction of a robust EHV-1-specific immune response was observed. Upon challenge infection, vaccinated horses were partially protected against disease as demonstrated by a significant reduction in clinical signs, nasal shedding and viremia levels. In addition, the NY03-based MLV was used to express the EIV H3 protein and immunogenicity was tested in horses. Expression of H3 was readily detected in NY03-H3-infected cells in vitro. Vaccination of horses resulted in the induction of a robust serological immune responses against two recent but genetically distinct EIV representatives, VA05 and NY-99, which were above the threshold predicted to be protective against development of clinical disease. © 2009 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	1048-1055
Journal	Vaccine
Volume	28
Issue number	4
Online published	6 Nov 2009
DOIs	https://doi.org/10.1016/j.vaccine.2009.10.123
Publication status	Published - 22 Jan 2010
Externally published	Yes

Research Keywords

Abortigenic
EHV-1
EIV
MLV

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access Output

10.1016/j.vaccine.2009.10.123

Other Access Options

Check CityUHK Library

Permanent Link

Right click to copy link

Cite this

@article{07ffd6cce1354484b1c62c323e7831b2,

title = "A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus",

abstract = "Vaccination is commonly used to control equine respiratory pathogens such as equine herpesvirus type 1 (EHV-1) and equine influenza virus (EIV). Here, we describe the generation and characterization of a recombinant EHV-1 modified live virus vaccine (MLV) based on a recent abortogenic EHV-1 strain, NY03. The immunogenicity and efficacy of the MLV was tested in horses in an EHV-1 vaccination/challenge experiment using the highly virulent neurovirulent EHV-1 strain OH03. Induction of a robust EHV-1-specific immune response was observed. Upon challenge infection, vaccinated horses were partially protected against disease as demonstrated by a significant reduction in clinical signs, nasal shedding and viremia levels. In addition, the NY03-based MLV was used to express the EIV H3 protein and immunogenicity was tested in horses. Expression of H3 was readily detected in NY03-H3-infected cells in vitro. Vaccination of horses resulted in the induction of a robust serological immune responses against two recent but genetically distinct EIV representatives, VA05 and NY-99, which were above the threshold predicted to be protective against development of clinical disease. {\textcopyright} 2009 Elsevier Ltd. All rights reserved.",

keywords = "Abortigenic, EHV-1, EIV, MLV, Abortigenic, EHV-1, EIV, MLV, Abortigenic, EHV-1, EIV, MLV",

author = "{Van de Walle}, {Gerlinde R.} and May, {Maeva A.} and Peters, {Sarah T.} and Metzger, {Stephan M.} and Rosas, {Cristina T.} and Nikolaus Osterrieder",

year = "2010",

month = jan,

day = "22",

doi = "10.1016/j.vaccine.2009.10.123",

language = "English",

volume = "28",

pages = "1048--1055",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "4",

}

TY - JOUR

T1 - A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus

AU - Van de Walle, Gerlinde R.

AU - May, Maeva A.

AU - Peters, Sarah T.

AU - Metzger, Stephan M.

AU - Rosas, Cristina T.

AU - Osterrieder, Nikolaus

PY - 2010/1/22

Y1 - 2010/1/22

N2 - Vaccination is commonly used to control equine respiratory pathogens such as equine herpesvirus type 1 (EHV-1) and equine influenza virus (EIV). Here, we describe the generation and characterization of a recombinant EHV-1 modified live virus vaccine (MLV) based on a recent abortogenic EHV-1 strain, NY03. The immunogenicity and efficacy of the MLV was tested in horses in an EHV-1 vaccination/challenge experiment using the highly virulent neurovirulent EHV-1 strain OH03. Induction of a robust EHV-1-specific immune response was observed. Upon challenge infection, vaccinated horses were partially protected against disease as demonstrated by a significant reduction in clinical signs, nasal shedding and viremia levels. In addition, the NY03-based MLV was used to express the EIV H3 protein and immunogenicity was tested in horses. Expression of H3 was readily detected in NY03-H3-infected cells in vitro. Vaccination of horses resulted in the induction of a robust serological immune responses against two recent but genetically distinct EIV representatives, VA05 and NY-99, which were above the threshold predicted to be protective against development of clinical disease. © 2009 Elsevier Ltd. All rights reserved.

AB - Vaccination is commonly used to control equine respiratory pathogens such as equine herpesvirus type 1 (EHV-1) and equine influenza virus (EIV). Here, we describe the generation and characterization of a recombinant EHV-1 modified live virus vaccine (MLV) based on a recent abortogenic EHV-1 strain, NY03. The immunogenicity and efficacy of the MLV was tested in horses in an EHV-1 vaccination/challenge experiment using the highly virulent neurovirulent EHV-1 strain OH03. Induction of a robust EHV-1-specific immune response was observed. Upon challenge infection, vaccinated horses were partially protected against disease as demonstrated by a significant reduction in clinical signs, nasal shedding and viremia levels. In addition, the NY03-based MLV was used to express the EIV H3 protein and immunogenicity was tested in horses. Expression of H3 was readily detected in NY03-H3-infected cells in vitro. Vaccination of horses resulted in the induction of a robust serological immune responses against two recent but genetically distinct EIV representatives, VA05 and NY-99, which were above the threshold predicted to be protective against development of clinical disease. © 2009 Elsevier Ltd. All rights reserved.

KW - Abortigenic

KW - EHV-1

KW - EIV

KW - MLV

KW - Abortigenic

KW - EHV-1

KW - EIV

KW - MLV

KW - Abortigenic

KW - EHV-1

KW - EIV

KW - MLV

UR - http://www.scopus.com/inward/record.url?scp=74149093531&partnerID=8YFLogxK

UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-74149093531&origin=recordpage

U2 - 10.1016/j.vaccine.2009.10.123

DO - 10.1016/j.vaccine.2009.10.123

M3 - RGC 21 - Publication in refereed journal

C2 - 19897066

SN - 0264-410X

VL - 28

SP - 1048

EP - 1055

JO - Vaccine

JF - Vaccine

IS - 4

ER -

A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus

Abstract

Research Keywords

UN SDGs

Access Output

Other Access Options

Permanent Link

Other Files and Links

Fingerprint

Cite this